222535-08-2

Upstream product

• 79290-07-6 ethyl 4-hydroxy-6-nitro-2-naphthalenecarboxylate 
• 157188-17-5 4-hydroxy-6-nitro-2-naphthoic acid ethyl ester acetate 
• 222535-05-9 4-benzyloxy-6-nitro-naphthalene-2-carboxylic acid ethyl ester 
• 222535-06-0 4-benzyloxy-6-nitro-2-naphthalenecarboxylic acid 
• 100-39-0 benzyl bromide 
• 222535-07-1 N-(tert-butyloxycarbonyl)-4-benzyloxy-6-nitro-2-naphthylamine 

Downstream Products

• 222835-54-3 N-(tert-butyloxycarbonyl)-N-(3-chloro-2-propen-1-yl)-4-benzyloxy-1-iodo-6-nitro-2-naphthylamine 
• 286374-28-5 (6-amino-4-benzyloxy-1-iodo-naphthalen-2-yl)-(3-chloro-allyl)-carbamic acid tert-butyl ester 
• 222835-55-4 N-(tert-butyloxycarbonyl)-N-(3-chloro-2-propen-1-yl)-6-(9-fluorenylmethyloxy-carbonylamino)-4-benzyloxy-1-iodo-2-naphthylamine 
• 222835-56-5 5-(benzyloxy)-3-(tert-butyloxycarbonyl)-1-chloromethyl-7-(9-fluorenylmethyloxy-carbonylamino)-1,2-dihydro-3H-benz[e]indole 

Relevant academic research and scientific papers

ASYMMETRIC CONJUGATE COMPOUNDS

The invention relates to compound of formula (I): A-X1-L-X2-B and salts, solvates and tautomers thereof, which are useful as medicaments, in particular as anti-proliferative agents and for use as a drug in an antibody-drug conjugate;

Design, synthesis and cytotoxicity evaluation of 1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]indole (seco-CBI) dimers

Three types of 1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]indole (seco-CBI) dimers were designed, synthesized and evaluated in vitro by NCI against nine types of cancer cells. Biological results showed that the antitumor activities of these seco-CBI dimers were strongly related to the position and length of the linker and generally with potency increasing in the order of C7-C7 dimers (22i-iv)50 values50 values0.01μM against all the cell lines and showed the highest overall potency of the agents examined (GMG=0.0120μM). Copyright (C) 2000 Elsevier Science Ltd.